To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System

References

• Ram K , Kamlesh K , Melanie JD . Liraglutide for type 2 diabetes mellitus. Expert Opin Biol Ther . 2011;7:951–959.
   Google Scholar
• Blonde L , Russell-Jones D . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes Metab . 2009;11(Suppl 3):26–34. doi:10.1111/j.1463-1326.2009.01075.x 19878259
   PubMed Web of Science ®Google Scholar
• Tanaka K , Saisho Y , Manesso E , et al. Effects of liraglutide monotherapy on beta cell function and pancreatic enzymes compared with metformin in Japanese overweight/obese patients with type 2 diabetes mellitus: a subpopulation analysis of the KIND-LM randomized trial. Clin Drug Investig . 2015;35(10):675–684. doi:10.1007/s40261-015-0331-5
   Web of Science ®Google Scholar
• Davies MJ , Bergenstal R , Bode B , et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA . 2015;314(7):687–699. doi:10.1001/jama.2015.9676 26284720
   PubMed Web of Science ®Google Scholar
• Kapitza C , Forst T , Coester HV , et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab . 2013;15(7):642–649. doi:10.1111/dom.12076 23368510
   PubMed Web of Science ®Google Scholar
• Rai S , Hulse A , Kumar P . Feasibility and acceptability of ambulatory glucose profile in children with type 1 diabetes mellitus: a pilot study. Indian J Endocrinol Metab . 2016;20(6):790–794. doi:10.4103/2230-8210.192894 27867881
   PubMedGoogle Scholar
• Garg SK , Akturk HK . Flash glucose monitoring: the future is here. Diabetes Technol Ther . 2017;19(S2):S1–S3.
   PubMed Web of Science ®Google Scholar
• Linong J , Xiaohui G , Lixin G , et al. A multicenter evaluation of the performance and usability of a novel glucose monitoring system in Chinese adults with diabetes. J Diabetes Sci Technol . 2017;11(2):290–295. doi:10.1177/1932296816662884 27559031
   PubMedGoogle Scholar
• Bailey T , Bode BW , Christiansen MP , et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther . 2015;17(11):787–794. doi:10.1089/dia.2014.0378 26171659
   PubMed Web of Science ®Google Scholar
• Sato T , Oshima H , Nakata K , et al. Accuracy of flash glucose monitoring in insulin treated patients with type 2 diabetes. J Diabetes Investig . 2019;10(3):846–850. doi:10.1111/jdi.12954
   Web of Science ®Google Scholar
• Stratton IM , Adler AI , Neil HA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ . 2000;321(7258):405–412. doi:10.1136/bmj.321.7258.405 10938048
   PubMed Web of Science ®Google Scholar
• Lachin JM , Genuth S , Nathan DM , et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial revisited. Diabetes . 2008;57(4):995–1001. doi:10.2337/db07-1618 18223010
   PubMed Web of Science ®Google Scholar
• Gerbaud E , Darier R , Montaudon M , et al. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care . 2019;42(4):674–681. doi:10.2337/dc18-2047 30728222
   PubMed Web of Science ®Google Scholar
• Xing Y , Chen J , Zhao L , et al. Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes. Endocr J . 2020;67(4):455–468. doi:10.1507/endocrj.EJ19-0530 31996492
   PubMed Web of Science ®Google Scholar
• Bedenis R , Price AH , Robertson CM , et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh type 2 diabetes study. Diabetes Care . 2014;37(12):3301–3308. doi:10.2337/dc14-0908 25239782
   PubMed Web of Science ®Google Scholar
• Schiavon M , Visentin R , Göbel B , et al. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab . 2021;23(8):1795–1805. doi:10.1111/dom.14394 33822469
   PubMed Web of Science ®Google Scholar
• Meier JJ , Rosenstock J , Hincelin-Méry A , et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care . 2015;38(7):1263–1273. doi:10.2337/dc14-1984 25887358
   PubMed Web of Science ®Google Scholar
• Nagakura J , Yamakawa T , Taguri M , et al. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes. Endocr J . 2016;63(3):239–247. doi:10.1507/endocrj.EJ15-0500 26743240
   PubMed Web of Science ®Google Scholar
• Bianchi C , Miccoli R , Del Prato S . Hyperglycemia and vascular metabolic memory: truth or fiction? Curr Diab Rep . 2013;13(3):403–410. doi:10.1007/s11892-013-0371-2 23456482
   PubMed Web of Science ®Google Scholar
• Cooper ME , El-Osta A . Epigenetics: mechanisms and implications for diabetic complications. Circ Res . 2010;107(12):1403–1413. doi:10.1161/CIRCRESAHA.110.223552 21148447
   PubMed Web of Science ®Google Scholar
• Lu J , Ma X , Zhou J , et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care . 2018;41(11):2370–2376. doi:10.2337/dc18-1131 30201847
   PubMed Web of Science ®Google Scholar
• Beck RW , Bergenstal RM , Riddlesworth TD , et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care . 2019;42(3):400–405. doi:10.2337/dc18-1444 30352896
   PubMed Web of Science ®Google Scholar
• Lu J , Ma X , Shen Y , et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther . 2020;22(2):72–78. doi:10.1089/dia.2019.0251 31524497
   PubMed Web of Science ®Google Scholar
• Lanspa MJ , Krinsley JS , Hersh AM , et al. Percentage of time in range 70 to 139 mg/dL is associated with reduced mortality among critically Ill patients receiving IV insulin infusion. Chest . 2019;156(5):878–886. doi:10.1016/j.chest.2019.05.016 31201784
   PubMed Web of Science ®Google Scholar
• Nauck M , Frid A , Hermansen K , et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care . 2009;32(1):84–90. doi:10.2337/dc08-1355 18931095
   PubMed Web of Science ®Google Scholar
• Zinman B , Gerich J , Buse JB , et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care . 2009;32(7):1224–1230. doi:10.2337/dc08-2124 19289857
   PubMed Web of Science ®Google Scholar
• Garber A , Henry R , Ratner R , et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised 52-week, Phase III, double-blind, parallel-treatment trial. Lancet . 2009;373(9662):473–481. doi:10.1016/S0140-6736(08)61246-5 18819705
   PubMed Web of Science ®Google Scholar
• Drucker DJ . The role of gut hormones in glucose homeostasis. J Clin Invest . 2007;117(1):24–32. doi:10.1172/JCI30076 17200703
   PubMed Web of Science ®Google Scholar
• Campbell JE , Drucker DJ . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab . 2013;17(6):819–837. doi:10.1016/j.cmet.2013.04.008 23684623
   PubMed Web of Science ®Google Scholar
• Guo N , Sun J , Chen H , et al. Liraglutide prevents diabetes progression in prediabetic OLETF rats. Endocr J . 2013;60(1):15–28. doi:10.1507/endocrj.EJ12-0094 22986487
   PubMed Web of Science ®Google Scholar
• Buteau J . GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab . 2008;34:S73–S77. doi:10.1016/S1262-3636(08)73398-6 18640589
   PubMed Web of Science ®Google Scholar
• Chen LN , Lyu J , Yang XF , et al. Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice. Int J Mol Med . 2013;32(4):892–900. doi:10.3892/ijmm.2013.1453 23877319
   PubMed Web of Science ®Google Scholar
• Yang J , Ao N , Du J , et al. Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats. Endocrine . 2015;49(1):106–118. doi:10.1007/s12020-014-0480-y 25471281
   PubMed Web of Science ®Google Scholar
• Seino Y , Rasmussen MF , Zdravkovic M , et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract . 2008;81(2):161–168. doi:10.1016/j.diabres.2008.03.018 18495285
   PubMed Web of Science ®Google Scholar
• Bi Y , Tong GY , Yang HJ , et al. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev . 2013;29(8):664–672. doi:10.1002/dmrr.2443 23955995
   PubMed Web of Science ®Google Scholar